NCT05098613View on ClinicalTrials.gov

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

CD19x22 CAR T Cells

Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.

Trial Locations (1)

80045

RECRUITING

University of Colorado Hospital, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER